How it works
Certican tablet 0.75 mg (EVEROLIMUS) 60’s^ treats cancer by stopping cancer cells from reproducing and by decreasing blood supply to the cancer cells.
Uses of Certican tablet 0.75 mg (EVEROLIMUS) 60’s^
What is it prescribed for?
Organ Transplant – Rejection ProphylaxisThis medicine is used to prevent the rejection of an organ transplant.
Advanced Breast CancerThis medicine is used in postmenopausal women with advanced hormone receptor-positive, HER2/neu-negative breast cancer in combination with exemestane, after the failure of treatment with letrozole or anastrozole.
Advanced Renal Cell Carcinoma (RCC)This medicine is used in the treatment of patients with advanced renal cell carcinoma (RCC) after the failure of treatment with sunitinib or sorafenib.
Pancreatic CancerThis medicine is used in the treatment of progressive neuroendocrine tumors of pancreatic origin with unresectable, locally advanced or metastatic disease.
Renal AngiomyolipomaThis medicine is used in the treatment of patients suffering from a renal angiomyolipoma and tuberous sclerosis complex that does not require an immediate surgery.
Advanced Neuroendocrine CarcinomaThis medicine is used in the treatment of patients suffering from neuroendocrine tumors of pancreatic, gastrointestinal, or lung origin.
Brain/Intracranial TumorThis medicine is used in the treatment of patients suffering from subependymal giant cell astrocytoma (SEGA), a low-grade brain tumor, associated with tuberous sclerosis complex (TSC).
Tuberous Sclerosis Complex (TSC)-Associated Partial-Onset SeizuresThis medicine is used along with other medicines for the treatment of patients suffering from TSC-associated partial onset seizures.
Concerns
Frequently asked questions
Onset of action
The amount of time required for this medicine to show its effect is not clinically established.
Duration of Effect
The amount of time for which this medicine remains active in the body is not clinically established.
Safe with Alchohol?
Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.
Is it habit forming?
No habit-forming tendencies were reported.
Usage in pregnancy?
This medicine is not recommended for use in pregnant women unless absolutely necessary. Discuss all the risks and benefits with your doctor before taking this medicine. Your doctor may prescribe a safer alternative based on your clinical condition.
Usage while breast-feeding?
This medicine is not recommended for use in breastfeeding women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before taking this medicine. Your doctor may advise you to discontinue breastfeeding or to discontinue the drug based on your clinical condition. Alternatively, Your doctor may prescribe a safer alternative.
When not to use?
Allergy
This medicine is not recommended for use in patients with a known allergy to Certican tablet 0.75 mg (EVEROLIMUS) 60’s^ , other rapamycin derivatives, or any other inactive ingredients present along with it.
Warnings
Warnings for special population
Pregnancy
This medicine is not recommended for use in pregnant women unless absolutely necessary. Discuss all the risks and benefits with your doctor before taking this medicine. Your doctor may prescribe a safer alternative based on your clinical condition.
Breast-feeding
This medicine is not recommended for use in breastfeeding women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before taking this medicine. Your doctor may advise you to discontinue breastfeeding or to discontinue the drug based on your clinical condition. Alternatively, Your doctor may prescribe a safer alternative.
General Warnings
Vaccination
The administration of live vaccines is not recommended during treatment with this medicine due to the increased risk of serious infections. Patients are advised to avoid contact with individuals who have received live vaccines. Patients are also recommended to be up to date with all required immunizations before initiating therapy with this medicine.
Blood glucose levels
This medicine may increase the serum blood glucose levels in some patients. Monitoring of fasting serum glucose levels is recommended before starting therapy with this medicine and periodically thereafter. It is recommended that blood glucose levels should be within control before initiating therapy with this medicine.
Cholesterol levels
This medicine may increase the cholesterol and triglyceride levels in some patients. Monitoring of fasting lipid profile is recommended before starting therapy with this medicine and periodically thereafter. It is recommended that lipid levels should be within control before initiating therapy with this medicine.
Wound healing and fluid accumulation
This medicine may delay wound healing and increase the risk of wound-related complications which may require surgical intervention. It also may cause fluid accumulation, including peripheral edema and other types of localized fluid collections which may lead to further complications.
Infections
The immunosuppressant effect of this medicine may decrease the resistance to infectious agents and may increase the risk of infections. Patients are advised to report any unusual symptoms such as a sore throat, pain or burning during urination, fever, chills, etc. to the doctor immediately. Appropriate corrective measures, dose adjustments, or replacement with a suitable alternative may be necessary based on the clinical condition of the patient.
Non-infectious pneumonitis
This medicine may cause non-infectious pneumonitis in some patients. Appropriate dose adjustments should be made based on the severity of the symptoms. Appropriate corrective measures or replacement with a suitable alternative may be necessary in some cases based on the clinical condition of the patient.
Angioedema
The use of this medicine, either alone or in combination with other medicines, may cause angioedema in some patients. Appropriate corrective measures, dose adjustments, or replacement with a suitable alternative may be necessary based on the clinical condition of the patient.
Proteinuria
This medicine may increase the presence of abnormal quantities of protein in the urine (proteinuria) when it is used along with cyclosporine in transplant patients. Monitoring of protein levels in urine is recommended when these medicines are used together. Appropriate dose adjustments or replacement with a suitable alternative may be necessary in some cases based on the clinical condition of the patient.
Infertility
Prolonged therapy with this medicine may cause male as well as female infertility. Patients with reproductive potential should discuss this risk with their physician before beginning treatment with this medicine.
Stomatitis/Mouth Sores
This medicine may cause mouth sores in some patients. Appropriate corrective measures, dose adjustments, or replacement with a suitable alternative may be necessary based on the clinical condition of the patient.
Hematologic abnormalities
This medicine should be used with caution in patients predisposed to hematologic changes due to the increased risk of severe hematologic abnormalities. These abnormalities may include decreased levels of hemoglobin, platelets, lymphocytes, white blood cells, etc. Periodic monitoring of complete blood counts is recommended during treatment with this medicine. Appropriate dose adjustments or replacement with a suitable alternative may be necessary based on the clinical condition of the patient.
Dosage
Missed Dose
Take the missed dose as soon as you remember. If it is almost time for your next dose, skip the missed dose. Do not double your dose to make up for the missed one.
Overdose
Seek emergency medical treatment or contact a doctor immediately in case of an overdose.
Interactions
Interaction with Medicines
Aliskiren moderate
Angiotensin converting enzyme inhibitors (ACEI’s) moderate
Darunavir severe
Adalimumab severe
Ketoconazole moderate
Food interactions
Consumption of grapefruit or grapefruit juice is not recommended during treatment with this medicine due to the increased risk of serious adverse effects.
General Instructions
Take this medicine exactly as advised by your doctor. Do not take in larger amounts than advised or share this medicine with others. Ensure that the treatment course is completed. Do not stop the use of this medicine without consulting your doctor.
References
medlineplus.gov – Everolimus [Internet]. Available from: https://medlineplus.gov/druginfo/meds/a609032.html [cited 28/7/2020]. 2020
Additional Information:
what are the adverse effects of Certican tablet 0.75 mg (EVEROLIMUS) 60’s^?
Leucopenia and hyperlipidaemia while used concomitantly with cyclosporin for microemulsion and corticosteroids. Infections, thrombocytopenia, anaemia, venous thromboembolism, pneumonia, diarrhoea, nausea, vomiting, abdominal pain, general pain, oedema, hypertension, acne, wound complication, myalgia, hepatitis, blood dyscrasias, anorexia, insomnia, headache, epistaxis, dry mouth, fatigue, chest pain, fever, weight loss. Less commonly congestive heart failure and impaired wound healing; hepatitis B reactivation and haemorrhage.
What happens if I miss a dose of Certican tablet 0.75 mg (EVEROLIMUS) 60’s^?
Prophylaxis of organ rejection: Adults: 0.75 mg twice daily. Advanced renal cell carcinoma: Adults: 10 mg once daily. Children: Not recommended.
One of the following licensed pharmacy from the nearest location will deliver Certican tablet 0.75 mg (EVEROLIMUS) 60’s^. The details of the licensed pharmacy shall be shared once you request the drugs and the respective pharmacy accepts your request based on valid prescription and availability.
Reviews
There are no reviews yet.